The first step to making a medicine is finding a target: you must understand the molecular mechanism of a disease, and then seek out a way to intervene with that process.
To play their part on the path to eliminating HCV, AbbVie’s health economics and outcomes research (HEOR) scientists are looking for targets of their own – ways to find the “missing millions” of people infected with undiagnosed or untreated HCV.
Even when testing efforts are successful, those testing positive don’t always end up getting treated, due to systemic and psycho-social barriers. So Steven Marx, director, HEOR, AbbVie and his team looked for a way to better understand if the missing millions were actually missing, or just not getting the care they needed.
“In the United States, we had limited information from a geographic standpoint about how many people had been tested and treated,” Marx says. “The data we did have varied from state to state; a lot of it was outdated and before recent outbreaks in several areas.”
Looking at data gleaned from the lab reports of over 17 million people tested for HCV in the United States, Marx’s team began developing a system that could identify pockets of untreated patients down to the three-digit zip code.
“Using machine learning, we came up with a way of predicting, with very high probability, whether patients who had been tested had received care,” Marx says. “We wanted to have a way of collecting this data and sharing the results with the HCV community at large … not only can this information help identify the need for an improved care cascade in specific areas, but it can also help clarify ‘what good looks like’, and ‘where good is’ in terms of reaching the missing millions in our country.”
Learn more: visit MappingHepC.com
Since health systems around the world face disparate challenges, there likely isn’t a one-size-fits-all strategy that can lead to worldwide elimination. Finding replicable strategies that work across populations with similar characteristics could be helpful, Pangerl says.
“What works well as an elimination strategy in an American prison may not work well in a homeless shelter in Germany,” he explains. “But let’s say someone with a prison population in a different country can see how that American prison successfully approached their problem – then, they can look at what was done and replicate it.”
This is the philosophical argument behind the concept of micro-elimination, where efforts are made to treat every last person living with HCV in a smaller, more targeted group. It may not seem like the fastest way to achieve the WHO goals for 2030, but the hope is that this type of customized approach may allow public health experts to address the societal barriers that make elimination so difficult. In other words, it’s not just about eliminating HCV, but figuring out how to do so in a sustainable, scalable way.
To help accomplish this goal, AbbVie is launching several micro-elimination projects around the world, funding and eliminating hepatitis C in smaller settings, with the goal of replicating elsewhere.
“Eliminating the disease is of course an incredible goal for those in the medical field; it’s the pinnacle of public health. But thinking of that one patient at a time, for me, is really important,” Pangerl says. “It’s not just a number. It’s about changing that one additional life.”
*In HCV, cure means that the virus is undetectable 12 weeks or more after completing treatment. This is also known as a “sustained virologic response”, or SVR. (Source: U.S. Department of Veteran Affairs)